Skip to content

Clinical Investigation To Evaluate Cerviron Ovules® in Symptomatic Vaginitis

A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04735705
Enrollment
50
Registered
2021-02-03
Start date
2021-04-01
Completion date
2021-09-09
Last updated
2023-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginitis and Vulvovaginitis

Keywords

Vaginitis, vaginal discharge, vaginal pH, vaginal microflora

Brief summary

CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in patients with symptomatic, non-specific, non-infectious vaginitis, and endogenous symptomatic infections. The secondary objective of this clinical investigation is the assessment of performance of the medical device by several additionally clinical outcomes (vaginal discharge, vaginal pH, microscopic characteristics of inflammatory cells and characteristics of vaginal microflora). Participants will also evaluate the degree of satisfaction related to the use of the medical device.

Detailed description

Vaginitis is the general term characterizing a spectrum of disorders of the vagina caused by infection, inflammation, or changes in the normal vaginal flora. Symptoms include abnormal vaginal discharge, odour, pruritus, pain, dysuria and/or discomfort. Moreover, vaginitis is responsible for the most common problems in clinical medicine, and it is the reason cited most often for visits to obstetricians and gynecologists. In the past years, the problem of vaginitis has all too often been ignored by the medical community or regarded merely as a minor annoyance to women. According to Gardner, Vaginitis must cause more unhappiness on earth than any other gynecologic disease. In addition to the many physical and emotional problems associated with vaginitis, the economic loss involved is of astronomic proportions. The most common causes of vaginitis are bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. Bacterial Vaginosis is the cause in 40% to 50% of cases in which a cause is identified, with vulvovaginal candidiasis accounting for 20% to 25% and trichomoniasis for 15% to 20% of cases. The standard of care currently is based on anti-infectious therapy. With the availability of complementary and alternative therapies and over-the-counter medications for vaginitis, many symptomatic women seek these products before or in addition to an evaluation by a medical provider. However, recurrence of vaginosis is frequent, and can include four or more episodes in one year. Non-infectious cases, including atrophic, irritant, and inflammatory vaginitis, are less common and account for 5% to 10% of vaginitis cases. Obtaining a medical history alone has been shown to be insufficient for accurate diagnosis of vaginitis and can lead to the inappropriate administration of medication. Therefore, a careful history, examination, and laboratory testing to determine the etiology of vaginal symptoms are needed. Information on sexual behaviors and practices, gender of sex partners, menses, vaginal hygiene practices (e.g., douching), and self-treatment with medications should be collected. Other causes of vaginitis There is no cause of vagini¬tis identified in up to 30% of women. These women may have a range of conditions, includ¬ing irritant or allergic vaginitis, atrophic vaginitis, or physiologic discharge. The presence of objective signs of vulvar inflammation in the absence of vaginal pathogens after laboratory testing suggests the possibility of mechanical, chemical, allergic, or other non-infectious causes of vulvovaginal signs or symptoms. Inflammatory vagi¬nitis is an uncommon condition characterized by purulent vaginal discharge, burning, and dyspa¬reunia, and should be considered in patients with these symptoms if no infectious cause is found. Inflammatory vaginitis is associated with low estrogen levels, such as in menopausal or perimenopausal women. Desquamative inflammatory vaginitis is a chronic inflammatory process involving both vagina and vestibule, occurring almost exclusively in white women, that responds well to topical anti-inflammatory therapy. Long-term maintenance therapy is frequently required. Irritant/allergic vaginitis is characterized by symptoms such as burning and soreness and signs such as vulvar erythema. Atrophic vaginitis is an uncommon condition that occurs as a consequence of estrogen deficiency and is characterized by symptoms such as thin, clear discharge, vaginal dryness, dyspareunia, itching. An examination of the vulva can indicate inflammation and thin and friable vaginal mucosa. Risk factors contributing to atrophic vaginitis are menopause, lactation, oophorectomy, radiation therapy, chemotherapy, immunologic disorders, premature ovarian failure, endocrine disorders, and antioestrogen medications. Aerobic vaginitis is a distinct vaginal condition, requiring different clinical management and with distinct clinical risks. (7) Aerobic vaginitis is defined by disruption in Lactobacillus dominance but is accompanied by more extreme inflammatory changes than BV and the presence of mainly aerobic enteric commensals or pathogens, including Group B Streptococcus (S. agalactiae), Enterococcus faecalis, Escherichia coli, and S. aureus. Streptococcus agalactiae (group B Streptococcus, GBS) vaginal pathogenicity is not uniformly acknowledged throughout the literature. GBS virulence for vagina was recognized in the past, as the organism has been observed to potentially cause local inflammation and discharge, as well as lactobacilli rarefaction. Cytolitytic vaginosis is another condition which has been recently described as an entity distinct from either normal flora or bacterial vaginosis. This condition, also called Doderlein's vaginitis, has numerous, active lactobacilli damaging epithelial cells because of extreme acidity and low pH. The bare nuclei and cellular debris that are seen during microscopy, should not be mistaken for leucocytes and cocci. Cerviron ovules® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens. This is the first clinical investigation on human subjects with this medical device, in which 50 patients will be enlisted, and which will take place in two research centres in Romania.

Interventions

DEVICECerviron

Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.

Sponsors

MDX Research
CollaboratorNETWORK
Perfect Care Distribution
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Adult females, aged 18 years to 65 years; * Subjects presenting two or more vaginal symptoms such as leucorrhoea, pruritus, burning sensation, erythema, pain, odour, dysuria, or dyspareunia; * Subjects with a diagnosis of either non-infectious vaginitis, or endogenous, symptomatic infection; * Negative for Gardnerella vaginalis, Candida albicans, Trichomonas vaginalis; * Subjects willing to provide signed informed consent to clinical investigation participation.

Exclusion criteria

* Subjects in menstrual period or suffering from menorrhagia; * Colpectomy; * Subjects with undiagnosed abnormal genital bleeding; * Subject with vulvar, vaginal or cervical cancer; * Known, active sexually transmitted infection (STI) in partner, as per anamnesis; * Subjects with HIV or other immunodeficiency; * Subjects with any pathology of the female reproductive organs; * Known allergy or hypersensitivity to the medical device ingredients; * Use of spermicides; * Use of diaphragm; * Concomitant topical or systemic anti-infective treatment; * Unable to comply with visit procedures; * Subjects included in other clinical investigations;

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit3 monthsSuccess is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation and/or pruritus and/or odor). Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.
Rate of Treatment-related Adverse Events in Subjects Participating in the Clinical Investigation3 monthsThe safety of CERVIRON ® as measured by the rate of treatmentrelated adverse events, including serious adverse events (SAEs), in subjects participating in the clinical investigation.

Secondary

MeasureTime frameDescription
Number of Participants With Change in Vaginal Microflora and Lactobacilli Count3 monthsThe change in Lactobacillus species as shown by microscopy
Number of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of Treatmentat 1, 2 and 3 monthsThe vaginal discharge assessed by the investigator by using a score: 0=absent 1. mild: insufficient for speculum collection 2. moderate: sufficient for speculum collection 3. abundant: visible at the introitus even before speculum introduction 4. purulent, abnormal discharge: visible at the introitus even before speculum introduction
Results in Patient Satisfaction's Scale (Likert Scale)3 monthsThe degree of satisfaction when using the medical device will be assessed using a five-point Likert Scale. The degree of satisfaction when using the medical device was assessed using a five-point Likert Scale, as very satisfied, satisfied, neutral, unsatisfied, and very unsatisfied.
Number of Participants With Change in Vaginal Inflammation3 monthsThe change in inflammatory and parabasal cells by microscopy
Number of Participants With Change in Vaginal pH Valuesat 1, 2 and 3 monthsDetermination of pH values compared to its normal values (3.8 - 4.5)

Countries

Romania

Participant flow

Participants by arm

ArmCount
Cerviron Vaginal Ovules
Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation. Cerviron: Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
47
Total47

Baseline characteristics

CharacteristicCerviron Vaginal Ovules
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
47 Participants
Age, Continuous41.23 Years
STANDARD_DEVIATION 10.27
Alcohol consumption0 Participants
Childbirth potential36 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
47 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
History of cancer2 Participants
Hydration36 Participants
Physical activity32 Participants
Reproductive life25 Participants
Rest/Day34 Participants
Sex: Female, Male
Female
47 Participants
Sex: Female, Male
Male
0 Participants
Sex life44 Participants
Subject in menopause9 Participants
Subject pregnant0 Participants
Tobacco consumption20 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 47
other
Total, other adverse events
3 / 47
serious
Total, serious adverse events
0 / 47

Outcome results

Primary

Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit

Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation and/or pruritus and/or odor). Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.

Time frame: 3 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Cerviron Vaginal OvulesNumber of Participants With the Same Gynaecological Conditions at the End of Treatment Visit13 Participants
Primary

Rate of Treatment-related Adverse Events in Subjects Participating in the Clinical Investigation

The safety of CERVIRON ® as measured by the rate of treatmentrelated adverse events, including serious adverse events (SAEs), in subjects participating in the clinical investigation.

Time frame: 3 months

ArmMeasureValue (NUMBER)
Cerviron Vaginal OvulesRate of Treatment-related Adverse Events in Subjects Participating in the Clinical Investigation3 AEs
Secondary

Number of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of Treatment

The vaginal discharge assessed by the investigator by using a score: 0=absent 1. mild: insufficient for speculum collection 2. moderate: sufficient for speculum collection 3. abundant: visible at the introitus even before speculum introduction 4. purulent, abnormal discharge: visible at the introitus even before speculum introduction

Time frame: at 1, 2 and 3 months

ArmMeasureGroupValue (NUMBER)
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentAbsent - 1 month2 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentAbsent - 2 months8 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentAbsent - 3 months9 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentMild - 1 month26 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentMild - 2 months21 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentMild - 3 months13 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentModerate - 1 month19 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentModerate - 2 months18 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentModerate - 3 months25 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentAbundant - 1 month0 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentAbundant - 2 months0 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentAbundant - 3 months0 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentPurulent - 1 month0 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentPurulent - 2 months0 participants
Cerviron Vaginal OvulesNumber of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of TreatmentPurulent - 3 months0 participants
Secondary

Number of Participants With Change in Vaginal Inflammation

The change in inflammatory and parabasal cells by microscopy

Time frame: 3 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal Inflammation32 Participants
Secondary

Number of Participants With Change in Vaginal Microflora and Lactobacilli Count

The change in Lactobacillus species as shown by microscopy

Time frame: 3 months

ArmMeasureGroupValue (NUMBER)
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal Microflora and Lactobacilli CountLactobacilli present30 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal Microflora and Lactobacilli CountLeukocytes present38 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal Microflora and Lactobacilli CountEnterobact. present0 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal Microflora and Lactobacilli CountSquamous epithelial cells present0 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal Microflora and Lactobacilli CountGardnerella vaginalis present2 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal Microflora and Lactobacilli CountTrich. vaginalis present0 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal Microflora and Lactobacilli CountCandida present2 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal Microflora and Lactobacilli CountYeast cells and filaments present2 Participants
Secondary

Number of Participants With Change in Vaginal pH Values

Determination of pH values compared to its normal values (3.8 - 4.5)

Time frame: at 1, 2 and 3 months

ArmMeasureGroupValue (NUMBER)
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal pH ValuesNormal - 1 month41 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal pH ValuesNormal - 2 months44 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal pH ValuesNormal - 3 months47 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal pH ValuesAbnormal - 1 month6 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal pH ValuesAbnormal - 2 months3 Participants
Cerviron Vaginal OvulesNumber of Participants With Change in Vaginal pH ValuesAbnormal - 3 months0 Participants
Secondary

Results in Patient Satisfaction's Scale (Likert Scale)

The degree of satisfaction when using the medical device will be assessed using a five-point Likert Scale. The degree of satisfaction when using the medical device was assessed using a five-point Likert Scale, as very satisfied, satisfied, neutral, unsatisfied, and very unsatisfied.

Time frame: 3 months

ArmMeasureGroupValue (NUMBER)
Cerviron Vaginal OvulesResults in Patient Satisfaction's Scale (Likert Scale)Very Satisfied39 Participants
Cerviron Vaginal OvulesResults in Patient Satisfaction's Scale (Likert Scale)Satisfied6 Participants
Cerviron Vaginal OvulesResults in Patient Satisfaction's Scale (Likert Scale)Neutral2 Participants
Cerviron Vaginal OvulesResults in Patient Satisfaction's Scale (Likert Scale)Unsatisfied0 Participants
Cerviron Vaginal OvulesResults in Patient Satisfaction's Scale (Likert Scale)Very Unsatisfied0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026